MajesTEC-2 Trial | Emma Searle, MBChB MA MRCP FRCPath PhD | ASH 2022

(5:39)

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myeloma

(45)

Results from the MajesTEC-2 and TRIMM-2 Clinical Trials for Patients With Multiple Myeloma

(6:45)

Teclistamab in Combination with Sub-Q Daratumumab and Lenalidomide in Myeloma Pts: MajesTEC-2

(6:59)

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma

(46)

MajesTEC-5: Phase II study of Tec-based induction in transplant-eligible newly diagnosed myeloma

(3:33)

Niels van de Donk, MD, PhD, Discusses MajesTEC-1 Follow-Up Data on Teclistamab in Multiple Myeloma

(8:49)

Elon Musk, son véritable projet – par Michel Onfray

(9:13)

L'ARENE du 02/02/2025, Invité: Majesté Bruno MVONDO, Chef de MINKOK -BITYILI A EBOLOWA II

(2:12:48)

Présentation de l'exposition Revoir Cimabue. Aux origines de la peinture italienne\

(1:13:)

The Malahit DSP2 SDR V2.4 Shortwave, AM, FM, MW, LW, AIR, CW, SSB, RTTY, And more Radio. Holy Cow!

(16:11)

Les révélations stupéfiantes venant du roi Louis XVI

(33:3)

DETRUIRE LES AUTELS SATANIQUES Vaincre les Terreurs de la Nuit | TFC | MAR4 FEV 2025 |

(6:52:52)

Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics

(58:)

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

(7:3)

Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022

(11:22)

Long-term follow-up results of the Phase I/II MajesTEC-1 trial

(1:13)

MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab

(1:53)

Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

(7:25)

Durability of Responses With Biweekly Dosing of Teclistamab in Pts With Relapsed/Refractory Myeloma

(5:6)

Updated results from MajesTEC-1

(2:43)

Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with MM

(6:48)

MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in RR multiple myeloma

(4:30)

MajesTEC-1: teclistamab for myeloma

(1:4)

MajesTEC-1: update on RP2D of teclistamab in R/R myeloma

(3:5)

A subgroup analysis of MajesTEC-1: teclistamab in multiple myeloma with high-risk features

(1:59)

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

(1:15)